Abstract

DEVELOPMENT AND VALIDATION OF A STABILTY INDICATING REVERSED PHASE (RP) - HPLC METHOD FOR THE QUANTITATIVEAND QUALITATIVE DETERMINATION OF SOFOSBUVIR & VELPATASVIR IN ORAL DOSAGE FORM

Khan Muhammad*, Syed Muhammad Ali Rizvi, Kashif Ahmed

ABSTRACT

Background: In phase two ranges, combined molecule like Sofosbuvir and Velpatasvir. While Sofosbuvir is nucleotide inhibitor polymerase (NPI) with NS5A inhibitor Velpatasvir are front-runner in case of symptom of hepatitis C’ (HCV) in the genotype two or three stages. Administrative Drug Benefits: In earlier the Sofosbuvir and ribavirin used for the treatment of hepatitis C, different clinical trials studies were pledged for genotype two or three levels as well. The Sofosbuvir and Velpatasvir attainment principal effectiveness against virologic treatment of several patients within 12 weeks, rejoined greater effectiveness at the end of mentioned time line. Sofosbuvir and Velpatasvir blended dose were found 99% comeback in HCV, type 2 viral influence, in case study of combined dose of Sofosbuvir and Velpatasvir found rare adverse effect so for.[1]

Keywords: Reverse phase HPLC isocratic method, Stability indicating method, Velpatasvir & Sofosbuvir Tablet.